MedTrace Logo

ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects

NCT05066698 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2022-10-25

No results posted yet for this study

Summary

The primary objective is to determine the efficacy of ST266 eye drops in healing persistent epithelial defects (PED). After 8 weeks of randomized, double-blind treatment, non-healers will enter into an additional 8-week open-label ST266 treatment period. All patients will be followed for 3-months post-treatment for monitoring of safety and maintenance of re-epithelialization.

Conditions

  • Persistent Corneal Epithelial Defect

Interventions

BIOLOGICAL

ST266

Topical ocular application: one drop four times a day for eight weeks

OTHER

0.67% Sodium Chloride Ophthalmic Solution

Topical ocular application: one drop four times a day for eight weeks

BIOLOGICAL

Open-label ST266

Open label extension for non-healers after completion of double-blind treatment phase: topical ocular application of one drop four times a day for eight weeks

Sponsors & Collaborators

  • IQVIA Biotech

    collaborator INDUSTRY

  • Noveome Biotherapeutics, formerly Stemnion

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-27
Primary Completion
2022-09-07
Completion
2022-09-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05066698 on ClinicalTrials.gov